SG Americas Securities LLC Sells 11,558 Shares of Dianthus Therapeutics, Inc. $DNTH

SG Americas Securities LLC lowered its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 62.3% in the first quarter, HoldingsChannel.com reports. The fund owned 7,007 shares of the company’s stock after selling 11,558 shares during the quarter. SG Americas Securities LLC’s holdings in Dianthus Therapeutics were worth $588,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $43,000. Seven Fleet Capital Management LP bought a new position in Dianthus Therapeutics during the fourth quarter worth about $604,000. Invesco Ltd. increased its position in Dianthus Therapeutics by 125.9% during the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock worth $4,182,000 after buying an additional 56,560 shares during the last quarter. XTX Topco Ltd acquired a new position in Dianthus Therapeutics during the fourth quarter worth approximately $550,000. Finally, Voloridge Investment Management LLC raised its stake in Dianthus Therapeutics by 80.5% in the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock valued at $1,627,000 after buying an additional 17,612 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 2.6%

NASDAQ DNTH opened at $95.76 on Wednesday. The company has a market cap of $5.24 billion, a price-to-earnings ratio of -23.19 and a beta of 1.20. The company has a 50 day moving average of $86.94 and a 200-day moving average of $70.77. Dianthus Therapeutics, Inc. has a 1-year low of $18.08 and a 1-year high of $98.70.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DNTH. Wedbush lifted their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Wells Fargo & Company began coverage on Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.82.

Insider Activity at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 8,224 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the transaction, the executive vice president owned 8,224 shares of the company’s stock, valued at $738,844.16. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares of the company’s stock, valued at $2,424,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 64,754 shares of company stock valued at $5,566,993 over the last quarter. 3.02% of the stock is owned by corporate insiders.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.